Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 bemarituzumab + mFOLFOX6 vs placebo + mFOLFOX6 in FGFR2b-positive advanced gastric/GEJ cancer
jRCT2031220049Phase 3Completed
- Sponsor
- Amgen
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing Bemarituzumab + mFOLFOX6 with Placebo + mFOLFOX6 (2 arms). Primary endpoint: Overall Survival in FGFR2b ≥ 10% 2+/3+ tumor cell staining participants. Started Mar 2022; status: completed.
02
Drugs
bemarituzumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2031220049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220049.